This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Leesar, M. A. Articles by Bolli, R. Search for Related Content PubMed Articles by Leesar, M. A. Articles by Bolli, R.

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Pretreatment With Intracoronary Enalaprilat Protects Human Myocardium During Percutaneous Coronary Angioplasty

Division of Cardiology, University of Louisville, Louisville, Kentucky.

Manuscript received November 3, 2006; revised manuscript received December 12, 2006, accepted January 1, 2007.

^_* Reprint requests and correspondence: Dr. Roberto Bolli, Division of Cardiology, University of Louisville, Louisville, Kentucky 40292. (Email: rbolli{at}louisville.edu).

Objectives: We tested the hypothesis that enalaprilat induces preconditioning (PC)-mimetic actions in patients with stable coronary artery disease.

Background: Angiotensin-converting enzyme (ACE) inhibitors increase the bioavailability of bradykinin, which induces cardiac PC.

Methods: Twenty-two patients undergoing coronary angioplasty were randomized to an intracoronary infusion of enalaprilat or placebo, followed 10 min later by a PC protocol.

Results: In control patients, the ST-segment shift was greater during the first inflation than during the second and third inflations, both on the intracoronary electrocardiogram (ECG) (21.0 ± 2.8 mm vs. 13.0 ± 2.0 mm and 13.0 ± 2.0 mm, p < 0.05) and the surface ECG (16.0 ± 4.0 mm vs. 10.0 ± 2.0 mm and 9.0 ± 2.0 mm, p < 0.05). In contrast, enalaprilat-pretreated patients showed no change in ST-segment shift during inflations on either the intracoronary or the surface ECG. During the first inflation, the ST-segment shift was significantly smaller in treated versus control patients. The chest pain score during the first inflation was also significantly smaller in treated patients versus control patients (33.0 ± 6.0 mm vs. 64.0 ± 6.0 mm) and did not change in treated patients during the second and third inflations, whereas it decreased significantly in control patients. In a subset of 6 patients, enalaprilat increased coronary blood flow during infusion, but this effect dissipated before the beginning of angioplasty.

Conclusions: Pretreatment with enalaprilat attenuates the manifestations of myocardial ischemia during angioplasty. This is the first in vivo evidence showing that an ACE inhibitor protects human myocardium, possibly via PC-mimetics actions, a novel property that might explain the cardioprotective actions of these drugs.

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   CBF = coronary blood flow   ECG = electrocardiogram   PC = preconditioning   PTCA = percutaneous transluminal coronary angioplasty

This article has been cited by other articles:

				M. White, H. Ross, S. Levesque, L. Whittom, G. B Pelletier, N. Racine, S. Meloche, and L. Voisin Effects of Angiotensin-Converting Enzyme Inhibitor Versus Valsartan on Cellular Signaling Events in Heart Transplant Ann. Pharmacother., May 1, 2009; 43(5): 831 - 839. [Abstract] [Full Text] [PDF]

				G. Niccoli, L. Altamura, A. Fabretti, G. A. Lanza, L. M. Biasucci, A. G. Rebuzzi, A. M. Leone, I. Porto, F. Burzotta, C. Trani, et al. Ethanol Abolishes Ischemic Preconditioning in Humans J. Am. Coll. Cardiol., January 22, 2008; 51(3): 271 - 275. [Abstract] [Full Text] [PDF]